Pharmaceutical Key Trends 2010

Pharmaceutical Key Trends 2010

Pharmaceutical Key Trends 2010

Pharma faces a number of key resistors to growth including the impending 2011 patent cliff which is set to erode $78 billion in global branded sales from drugs facing patent expiry over the 201014 period (plus $32 billion from continued erosion of already expired brands). Price cuts, reimbursement restrictions and growing regulatory pressure are further set to limit sales growth going forward. ( http://www.bharatbook.com/detail.asp?id=134235&rt=Pharmaceutical-Key-Trends-2010.html )

Scope

* Overview of the key drivers and resistors facing Pharma, Biotech and generics players out to 2014

* Analysis of recent regulatory changes in the US, EU and emerging markets and their impact on pricing and reimbursement, drug development and marketing

* Examination of key global and country-specific issues facing both biosimilars and generics players

* Assessment of the impact of the global economic downturn on the Pharma and Biotech sectors and their respective counter strategies

Highlights

Annual sales growth of pharmaceuticals in the emerging markets is already double-digit, providing a key opportunity for Pharma. Revenue streams in these markets can be derived from launching branded off-patent drugs, branded generics, and local brands owned or licensed by the acquiring pharma company.

Pharma is moving away from the ""me-too"" and increasingly genericized primary care market towards more high value biologic therapies in secondary care as well as more niche markets; markets with little or no existing competition, and which despite their smaller size (in terms of patient numbers) are still commercially attractive.

To maintain profitability in the face of slowing sales to 2014, pharma companies have implemented a number of cost-cutting measures (in addition to strategic repositioning and diversification strategies) in order to boost profitability going forward.

Reasons to Purchase

* Examine the combined prescription drug sales forecasts for the top 50 Pharma out to 2014 by molecule type, product source, geography and therapy area

* Identify the key factors impacting Pharma's R&D productivity as well as the solutions companies are implementing to strengthen their R&D efforts

* Assess key drivers behind Pharma's M&A activity and its role in boosting profits by opening up new access to new markets as well as cutting costs

To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=134235&rt=Pharmaceutical-Key-Trends-2010.html

Or

Contact us at :

Bharat Book Bureau

Tel: +91 22 27578668

Fax: +91 22 27579131

Email: info@bharatbook.com

Website: www.bharatbook.com

Blog: http://bharatbookresearch.blogspot.com

Follow us on twitter: http://twitter.com/3bbharatbook

by:

POST COMMENT

Step-by-step guide to install the Edge DS with the latest Driver/Kernel/Firmware How to look-after your roof How to Cope With Losing a Pet Stainless Steel Teapots - Keep Your Tea Hot 350-030 practice test Stepping into various gaskets Caring for a Teak Bench Knowing How To Curb Appetite A Whirlwind Of Fun At The Rainbow's End Theme Park Spa Break in Maldives, a delightful sojourn Chicken Comforts when Building your Chicken Coop Replogle Globes Kayak Add-ons You Require For Your Personal Pygmy Kayaks